Style | Citing Format |
---|---|
MLA | Hosseini F, et al.. "A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia." Clinical Nutrition ESPEN, vol. 59, no. , 2024, pp. 378-386. |
APA | Hosseini F, Hemmati A, Takabi FS, Naeini F, Shab Bidar S (2024). A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia. Clinical Nutrition ESPEN, 59(), 378-386. |
Chicago | Hosseini F, Hemmati A, Takabi FS, Naeini F, Shab Bidar S. "A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia." Clinical Nutrition ESPEN 59, no. (2024): 378-386. |
Harvard | Hosseini F et al. (2024) 'A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia', Clinical Nutrition ESPEN, 59(), pp. 378-386. |
Vancouver | Hosseini F, Hemmati A, Takabi FS, Naeini F, Shab Bidar S. A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia. Clinical Nutrition ESPEN. 2024;59():378-386. |
BibTex | @article{ author = {Hosseini F and Hemmati A and Takabi FS and Naeini F and Shab Bidar S}, title = {A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia}, journal = {Clinical Nutrition ESPEN}, volume = {59}, number = {}, pages = {378-386}, year = {2024} } |
RIS | TY - JOUR AU - Hosseini F AU - Hemmati A AU - Takabi FS AU - Naeini F AU - Shab Bidar S TI - A Dose–Response Meta-Analysis of Randomized Clinical Trials Investigating the Effects of Omega-3 Supplementation on Body Weight in Patients With Cancer Cachexia JO - Clinical Nutrition ESPEN VL - 59 IS - SP - 378 EP - 386 PY - 2024 ER - |